doi:10.3969/j.issn.1674-490X.2022.06.005

Abstract

Abstract: Objective To analyze the correlation between helicobacter pylori antibody, pepsinogen, gastrin-17 and the clinical stage of gastric cancer. Methods The clinical data of 120 patients with gastric cancer treated in our hospital from April 2015 to April 2017 were retrospectively analyzed. 70 gastritis patients were used as controls to compare the positive rate of serum helicobacter pylori antibody, pepsinogen level and gastrin-17 level in patients with gastric cancer at different clinical stages. Spearman correlation was used to analyze the correlation between the above factors and gastric cancer. Results The positive rate of helicobacter pylori antibody in patients with gastric cancer was higher than that in the control group(P<0.05), and the positive rate of helicobacter pylori antibody in patients with stage Ⅰ, Ⅱ, Ⅲ and Ⅳ increased gradually. The levels of serum pepsinogen Ⅱ, gastrin-17 in patients with gastric cancer were higher than those in the control group, and the levels of pepsinogen Ⅰ were lower than those in the control group(P< 0.05). The levels of serum pepsinogen Ⅱ and gastrin-17 in patients with stage Ⅰ, Ⅱ, Ⅲ and Ⅳ increased gradually, and the levels of pepsinogen I decreased gradually. In the multiple linear regression analysis with clinical stage of gastric cancer, the regression coefficients of helicobacter pylori antibody, pepsinogen Ⅱ and gastrin-17 were 0.396, 0.059 and 0.047, respectively, the regression coefficient of pepsinogen I was -0.040.Conclusion Helicobacter pylori antibody, pepsinogen and gastrin-17 are closely related to the clinical stage of gastric cancer.

Key words: helicobacter pylori antibody, pepsinogen, gastrin-17, gastric cancer

CLC Number:

References

[1] 赵会懂,靳海峰.NGF-TrkA信号通路在胃癌进展和预后中的作用及机制研究[J].解放军医药杂志, 2018, 30(6): 113-116. DOI: 10.3969/j.issn.2095-140X.2018.06.029.
[2] 王晓勋.肿瘤微环境中癌相关成纤维细胞促进胃癌转移的机制研究[D].沈阳:中国医科大学, 2018: 58-60.
[3] 胡君璧,赵艳,李雅睿,等.microRNAs与胃癌早期诊断、化疗耐药及预后的作用机制研究进展[J].临床医学研究与实践, 2017, 2(35): 187-189, 192. DOI: 10.19347/j.cnki.2096-1413.201735091.
[4] 邢志芳,吕攀攀.幽门螺旋杆菌与胃癌致病机制及治疗方案相关性的研究进展[J].检验医学与临床, 2017, 14(20): 3123-3125. DOI: 10.3969/j.issn.1672-9455.2017.20.059.
[5] 刘应玲,陈思,洪海鸥,等.血清胃蛋白酶原、胃泌素17和幽门螺杆菌检测在胃癌前病变诊断中的价值[J].安徽医科大学学报, 2017, 52(8): 1227-1231. DOI: 10.19405/j.cnki.issn1000-1492.2017.08.028.
[6] 陈欢,张祎,蔡小旭,等.基质金属蛋白酶-7启动子(-181A/G)基因多态性与消化道肿瘤易感性的Meta分析[J].现代肿瘤医学, 2018, 26(16): 2578-2584. DOI: 10.3969/j.issn.1672-4992.2018.16.023.
[7] 韩艳珍,薛建鹏,胡加亮,等.基质金属蛋白酶抑制剂类抗肿瘤药物临床研究进展[J].药学进展, 2018, 42(2): 129-137.
[8] 王书彩,朱希燕,李琛琮,等.血清胃泌素17及胃蛋白酶原联合¹⁴C呼气试验在健康体检人群胃癌筛查中的价值研究[J].中国全科医学, 2018, 21(13): 1585-1588. DOI: 10.3969/j.issn.1007-9572.2018.13.015.
[9] 李卫兵,王奎明,侯炜炜,等.胃蛋白酶原、胸苷激酶-1联合检测在胃癌筛查中的应用[J].中国医药导报, 2018, 15(10): 75-78.
[10] 杨小敏,张娓.血清胃蛋白酶原和促胃液素-17在胃癌前病变临床诊断中的意义[J].中国中西医结合消化杂志, 2018, 26(4): 370-373.
[11] 张华,乐嫣,张艺青,等.联合检测胃蛋白酶原、胃泌素-17及CEA、CA19-9在胃癌诊断中的应用[J].标记免疫分析与临床, 2018, 25(1): 5-7, 43. DOI: 10.11748/bjmy.issn.1006-1703.2018.01.002.
[12] 刘林,路荣,陈莹,等.胃镜联合血清胃蛋白酶原诊断高危Hp相关性胃癌的价值研究[J].海南医学院学报, 2018, 24(2): 185-187. DOI: 10.13210/j.cnki.jhmu.20180105.024.
[13] PEREIRA-MARQUES J, FERREIRA R M, PINTO-RIBEIRO I, et al. Helicobacter pylori infection, the gastric microbiome and gastric cancer[J]. Adv Exp Med Biol, 2019, 1149: 195-210. DOI: 10.1007/5584_2019_366.
[14] 崔国艳,申俞,李云飞,等.胃癌组织中PTEN、RUNX3基因甲基化与幽门螺杆菌感染的关系[J].山西医科大学学报, 2022, 53(1): 14-18. DOI: 10.13753/j.issn.1007-6611.2022.01.003.
[15] 白忠秀,王艳,孟红军.幽门螺杆菌阳性胃黏膜病变和胃癌中miR-93的表达及与临床病理特征的相关性研究[J].解放军医药杂志, 2021, 33(11): 17-21. DOI: 10.3969/j.issn.2095-140X.2021.11.005.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 14-21.
[2]	. [J]. Journal of Hebei Medical College for Continuing Education, 2021, 38(4): 18-22.
[3]	. [J]. Medical Reserch and Education, 2018, 35(2): 13-16.
[4]	. [J]. Medical Reserch and Education, 2017, 34(1): 33-38.
[5]	LIU Bo,CHENG Shujie. Research on inhibition of human gastric cancer SGC-7901 cells and drug-resistance in vitro by Diosbulbin B [J]. Medical Reserch and Education, 2014, 31(3): 6-10.
[6]	YANG Nan,FENG Yichao. Advance on the relationship between COX-2 and gastric cancer [J]. Medical Reserch and Education, 2013, 30(5): 83-86,91.
[7]	ZHAO Jisen,CHENG Shujie,LI Pengkai. Research on inhibition of gastric cancer cell line SGC-7901 proliferation by diosbulbin B [J]. Medical Reserch and Education, 2013, 30(3): 13-15,19.